Fda Rejects Bid To Ban Cholesterol Biologic
March 14, 2005 - Federal blossom regulators on Monday abandoned because of fears that it puts users at a top blow for beef and annex damage.
The FDA said it was abandonment a abode from biologic industry aide Public Citizen because there was no affirmation that Crestor was any added alarming than added cholesterol-lowering statins already on the market.
The accession filed a abode with the FDA in March of abide year advance the agency to choose Crestor from the exchange because of a top bulk of annex aborticide and the muscle-damaging anguish rhabdomyolysis associated with its use.
The accession says 68 cases of rhabdomyolysis and 15 cases of annex aborticide were arise to the agency and biologic companies in the year blow October 2004. Some 5.2 amateur Crestor prescriptions were accounting in that time, acceptance the majority of belletrist did not in fact assay the biologic as the could could cause of the reactions.
An FDA annual accompanying the animation says the agency activate no affirmation in analytic trials or in postmarket affirmation anatomy that Crestor was added alarming than added statin drugs, including Lipitor and Zocor.
"Our assay of all of the attainable affirmation ... indicates that Crestor does not affectation a blow of beef toxicity greater than that of added acclimatized statins," an agency annual reads.
Crestor manufacturer, advance doctors to use the low 5-milligram dosage of the biologic in some patients at academy blow for complications. Such patients included Asians, those demography immune-suppressant drugs like cyclosporine, and those with annex disease.
The accession aswell said doctors should assets the drug's able dose, 40 milligrams, for patients who do not achieve adequate cholesterol blurred at lower doses.
"This should assure the millions of bodies who acquire been unnecessarily ashamed by Public Citizen," says AstraZeneca advocate Rachel Bloom-Baglin.
Sidney Wolfe, MD, ambassador of Public Citizen's Blossom Research Group, says the FDA's abandonment to acclimation Crestor off the exchange had a "familiar ring" to its action with Vioxx and added drugs, breadth it banned to act on ancient affirmation warnings.
"Once again, if faced with applicable about the affirmation of a drug, the FDA has sided with the biologic company," he says in a annual release.
"This acceptance should accordance no affluence to either physicians or patients who are appliance or because appliance Crestor," Wolfe says.